Tags

Type your tag names separated by a space and hit enter

Obesity is not strongly associated with increased risk for febrile neutropenia during levofloxacin prophylaxis in patients with hematological malignancies receiving intermediate-risk myelosuppressive chemotherapy.
J Oncol Pharm Pract 2019; :1078155219890403JO

Authors+Show Affiliations

Department of Pharmacy, Huntsman Cancer Institute, Salt Lake City, USA.Department of Pharmacy, Huntsman Cancer Institute, Salt Lake City, USA.Department of Pharmacy, Huntsman Cancer Institute, Salt Lake City, USA. Department of Pharmacy, University of Utah Health, Salt Lake City, USA.Department of Pharmacy, University of Utah Health, Salt Lake City, USA. Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31810423

Citation

Kurtti, Amanda, et al. "Obesity Is Not Strongly Associated With Increased Risk for Febrile Neutropenia During Levofloxacin Prophylaxis in Patients With Hematological Malignancies Receiving Intermediate-risk Myelosuppressive Chemotherapy." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 2019, p. 1078155219890403.
Kurtti A, Fritz K, Elofson-Disney K, et al. Obesity is not strongly associated with increased risk for febrile neutropenia during levofloxacin prophylaxis in patients with hematological malignancies receiving intermediate-risk myelosuppressive chemotherapy. J Oncol Pharm Pract. 2019.
Kurtti, A., Fritz, K., Elofson-Disney, K., & Benefield, R. (2019). Obesity is not strongly associated with increased risk for febrile neutropenia during levofloxacin prophylaxis in patients with hematological malignancies receiving intermediate-risk myelosuppressive chemotherapy. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, p. 1078155219890403. doi:10.1177/1078155219890403.
Kurtti A, et al. Obesity Is Not Strongly Associated With Increased Risk for Febrile Neutropenia During Levofloxacin Prophylaxis in Patients With Hematological Malignancies Receiving Intermediate-risk Myelosuppressive Chemotherapy. J Oncol Pharm Pract. 2019 Dec 6;1078155219890403. PubMed PMID: 31810423.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Obesity is not strongly associated with increased risk for febrile neutropenia during levofloxacin prophylaxis in patients with hematological malignancies receiving intermediate-risk myelosuppressive chemotherapy. AU - Kurtti,Amanda, AU - Fritz,Kelly, AU - Elofson-Disney,Kathryn, AU - Benefield,Russell, Y1 - 2019/12/06/ PY - 2019/12/8/entrez PY - 2019/12/8/pubmed PY - 2019/12/8/medline KW - Levofloxacin prophylaxis KW - neutropenia prophylaxis KW - obesity SP - 1078155219890403 EP - 1078155219890403 JF - Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners JO - J Oncol Pharm Pract SN - 1477-092X UR - https://www.unboundmedicine.com/medline/citation/31810423/Obesity_is_not_strongly_associated_with_increased_risk_for_febrile_neutropenia_during_levofloxacin_prophylaxis_in_patients_with_hematological_malignancies_receiving_intermediate-risk_myelosuppressive_chemotherapy L2 - http://journals.sagepub.com/doi/full/10.1177/1078155219890403?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -